HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations

被引:27
作者
Di Stefana, V
Mattiussi, M
Sacchi, A
D'Orazi, G
机构
[1] Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy
[2] Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy
来源
FEBS LETTERS | 2005年 / 579卷 / 25期
关键词
HIPK2; p53; phosphorylation; proteasomal degradation; MDM2; nuclear export;
D O I
10.1016/j.febslet.2005.09.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We address here the involvement of the homeodomain-interacting protein kinase 2 (HIPK2)/p53 complex on MDM2 regulation following apoptotic DNA damage. Our results provide a plausible transcriptional (p53-dependent) and posttranscriptional (p53-independent) double mechanism by which HIPK2 accomplishes MDM2 downmodulation. First, in wtp53-carrying cells HIPK2-dependent p53Ser46 phosphorylation selectively inhibits MDM2 at transcriptional level. Secondly, HIPK2 interacts with MDM2 in vitro and in vivo and promotes MDM2 nuclear export and proteasomal degradation, in p53-null cellular context. This p53-independent effect is likely mediated by HIPK2 catalytic activity and we found that HIPK2 phosphorylates MDM2 in vitro. In response to DNA damage, depletion of HIPK2 by RNA-interference abolishes MDM2 protein degradation. We propose that HIPK2 contributes to drug-induced modulation of MDM2 activity at transcriptional (through p53Ser46 phosphorylation) and posttranscriptional (through p53-independent subcellular re-localization and proteasomal degradation) levels. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:5473 / 5480
页数:8
相关论文
共 49 条
[1]  
Alarcón R, 1999, CANCER RES, V59, P6046
[2]   Post-translational modifications and activation of p53 by genotoxic stresses [J].
Appella, E ;
Anderson, CW .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (10) :2764-2772
[3]  
Ashcroft M, 1999, MOL CELL BIOL, V19, P1751
[4]   Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis [J].
Busino, L ;
Chiesa, M ;
Draetta, GF ;
Donzelli, M .
ONCOGENE, 2004, 23 (11) :2050-2056
[5]  
Chang YC, 1998, CELL GROWTH DIFFER, V9, P79
[6]  
Chène P, 2004, MOL CANCER RES, V2, P20
[7]   Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis [J].
D'Orazi, G ;
Cecchinelli, B ;
Bruno, T ;
Manni, I ;
Higashimoto, Y ;
Saito, S ;
Gostissa, M ;
Coen, S ;
Marchetti, A ;
Del Sal, G ;
Piaggio, G ;
Fanciulli, M ;
Appella, E ;
Soddu, S .
NATURE CELL BIOLOGY, 2002, 4 (01) :11-19
[8]   HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage [J].
Di Stefano, V ;
Soddu, S ;
Sacchi, A ;
D'Orazi, G .
ONCOGENE, 2005, 24 (35) :5431-5442
[9]   HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function [J].
Di Stefano, V ;
Blandino, G ;
Sacchi, A ;
Soddu, S ;
D'Orazi, G .
ONCOGENE, 2004, 23 (30) :5185-5192
[10]   Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis [J].
Di Stefano, V ;
Rinaldo, C ;
Sacchi, A ;
Soddu, S ;
D'Orazi, G .
EXPERIMENTAL CELL RESEARCH, 2004, 293 (02) :311-320